Autolus Therapeutics plc Stock Analysis & AI Score
Autolus Therapeutics plc (AUTL) has an ST Score of 52.4 (B-), driven by its Sentiment (A+) and held back by its Valuation (D). Analysts rate it Buy with a $8.87 price target (+364.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Autolus Therapeutics plc (AUTL) has an ST Score of 52.4 (B-), driven by its Sentiment (A+) and held back by its Valuation (D). Analysts rate it Buy with a $8.87 price target (+364.4% upside).
- Strongest
- SentimentA+
- Weakest
- ValuationD
All factor grades
- SentimentA+
- ForecastA
- GrowthA-
- MomentumB
- ProfitabilityD+
- Financial StrengthD+
- ValuationD
- Piotroski3/9
Contact
AUTL stock: frequently asked questions
What is AUTL's ST Score?
Autolus Therapeutics plc (AUTL) has an ST Score of 52.4 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is AUTL a buy, hold, or sell?
Analysts rate AUTL a Buy, with a price target of $8.87 (+364.4% vs the current price). Our ST Score grades it B- (52.4/100). The ST Score is a data-driven signal, not a recommendation.
What are AUTL's factor grades?
Valuation D, Profitability D+, Financial Strength D+, Momentum B, Growth A-, Forecast A, Sentiment A+.
What is AUTL's valuation grade?
Autolus Therapeutics plc (AUTL) earns a valuation grade of D, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is AUTL's growth grade?
Autolus Therapeutics plc (AUTL) earns a growth grade of A-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is AUTL's profitability grade?
Autolus Therapeutics plc (AUTL) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is AUTL's financial strength grade?
Autolus Therapeutics plc (AUTL) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for AUTL?
The average analyst price target for Autolus Therapeutics plc (AUTL) is $8.87 from 14 analysts, which is +364.4% versus the recent price of $1.91.
What is AUTL's Piotroski score?
Autolus Therapeutics plc (AUTL) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.